You are here: Industry Insights > Allergan

News List

Allergan successfully completes ZELTIQ Aesthetics acquisition cphi-online
May 02, 2017
Acquisition adds best-in-class body contouring business to Allergan's facial aesthetics, plastic surgery and regenerative medicine businesses.
Allergan partners with TARGET PharmaSolutions to advance NASH research europeanpharmaceuticalreview
April 24, 2017
Allergan will collaborate with TARGET PharmaSolutions, a clinical data company focused on real world evidence, on its TARGET-NASH study.
Novartis expands development programs for NASH with Allergan clinical partnership europeanpharmaceuticalreview
April 21, 2017
Novartis has entered into a clinical trial agreement with Allergan to conduct a Phase IIb study, involving the combination of a Novartis’ FXR agonist and Allergan’s cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH).
Allergan and Novartis in Clinical Collaboration contractpharma
April 19, 2017
Will evaluate use of Allergan's cenicriviroc and Novartis lead FXR agonist to treat NASH
Novartis Collaborates With Allergan On NASH - Quick Facts nasdaq
April 18, 2017
(RTTNews.com) - Novartis ( NVS ) said that it has entered into a clinical trial agreement with Allergan plc to conduct a Phase IIb study, involving the combination of a Novartis FXR agonist and Allergan's cenicriviroc or CVC for the treatment of non-alcoh
Allergan reports topline Phase II data supporting advancement of Botox for the treatment of MDD cphi-online
April 11, 2017
Botox is currently being studied as a potential treatment option for adult patients with moderate to severe MDD.
Allergan Names Senior Vice President of Global Investor Relations & Strategy americanpharmaceuticalreview
April 10, 2017
Allergan has announced that Daphne Karydas will join the Company as Senior Vice President of Global Investor Relations and Strategy, effective April 17, 2017.
Allergan signs up to Editas’ genome editing tech pharmatimes
March 16, 2017
Allergan has secured itself exclusive access to Editas Medicine’s genome-editing ocular programmes under a strategic research and development pact between the two firms.
Allergan and Editas Medicine all set to discover and develop CRISPR genome editing medicines for eye cphi-online
March 16, 2017
Alliance brings together eye care and CRISPR innovators to develop transformative medicines for patients.
Allergan and Editas Medicine Enter to Discover and Develop CRISPR Genome Editing Medicines for Eye D americanpharmaceuticalreview
March 15, 2017
Allergan and Editas Medicine have entered into a strategic research and development alliance under which Allergan will receive exclusive access and the option to license up to five of Editas Medicine's genome-editing ocular programs, including its lead pr

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page